Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 12, 2026
Spero Therapeutics, Inc. (SPRO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $9.6 million. As of Jun 30, 2026 it held $50.8 million in cash and investments and $2.0 million in total debt.
Revenue
$0
Net income
$-9.55M
-461.9% vs year-ago quarter
Operating cash flow
$-5.36M
+69.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.16
-433.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
58.23M
+3.5% vs year-ago quarter
Net cash
$48.73M
Q2 FY2026
Operating margin
47.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1701108
- Former names
- Spero Therapeutics, LLC (until Mar 21, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $12.6M | $0 | $0 |
| Operating income | -$9.9M | -$7.5M | $31.4M | -$7.9M | -$2.4M |
| Net income | -$9.6M | -$7.2M | $31.5M | -$7.4M | -$1.7M |
| Diluted EPS | -$0.16 | -$0.13 | $0.46 | -$0.13 | -$0.03 |
| Operating cash flow | -$5.4M | $15.9M | -$8.4M | $17.4M | -$17.7M |
| Total assets | $52.8M | $59.0M | $68.9M | $54.2M | $62.1M |
| Total liabilities | $8.6M | $6.1M | $9.9M | $27.7M | $29.3M |
| Stockholders' equity | $44.2M | $52.9M | $59.0M | $26.5M | $32.8M |
| Cash and investments | $50.8M | $56.1M | $40.3M | $48.6M | $31.2M |
| Total debt | $2.0M | $2.5M | $2.9M | $3.4M | $3.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 28, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure, Other events
|
Jul 14, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 25, 2026 | Jun 23, 2026 |
All 515 Spero Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.